The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...

Nearly every disease has an inflammatory component, but blood tests can't pinpoint inflammation in specific organs or tissues ...

Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

BENGALURU: When the first outbreak happened in Pune, all heads turned and started to panic. What was this new infectious ...

Methane is a powerful greenhouse gas, and cows are a major source of it. A group of scientists is developing a proof of ...

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, biomarkers, and other cancer treatments, will be highlighted at the American ...

NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum antiviral drug NV-387, a drug that the Bird Flu ...

I know there is both a growing interest in – and quite a bit of confusion about – the state of COVID-19 antibody testing. I wanted to take a moment to clear up some of the confusion.

The trial will see healthy volunteers infected with dengue to test the impact of AbViro’s monoclonal antibody therapy.

A man who took part in a clinical trial for the development of a Covid vaccine has lashed out at the lingering effects.

The ACP guideline, published in Annals of Internal Medicine, includes three recommendations centered around monotherapy: ...